Appendix



ICD-10 Codes

The 'core' disease classification of ICD-10-AM is the three character code, which is the mandatory level of coding for international reporting to the World Health Organisation (WHO) for general international comparisons. This core set of codes has been expanded to four and five character codes so that important specific disease entities can be identified, while also maintaining the ability to present data in broad groups to enable useful and understandable information to be obtained. Its structure is designed principally to facilitate epidemiological analysis.

Table 1. Eurostat 65 Cause of Death Shortlist (+9) accessed via PHIS relevant for Respiratory Disease used in body of report

Description	ICD-10 Codes
All Causes of Death	A00 - Y89
Neoplasms	C00 - D48
Diseases of the Cardiovascular System	100 - 199
Diseases of the Respiratory System	J00 - J99
Influenza	J10 - J11
Pneumonia	J12 - J18
Chronic Lower Respiratory Disease	J40 - J47
Asthma	J45 - J46
Other Diseases of the Respiratory System	Remainder of J00 - J99
Cancer of the Trachea, Bronchus and Lung	C33, C34

Table 2. ICD-10 codes used for hospitalisation data for respiratory conditions, adapted from the British Lung Foundation.

Classification of respiratory condition	ICD-10code
Abnormalities of breathing	R06
Acute bronchiolitis	J21
Acute bronchitis	J20
Acute lower respiratory infection (unspecified)	J22
Acute URTI	J00, J01, J02, J03, J04, J05, J06
Asthma	J45, J46
COPD	J40, J41, J42, J43, J44, J47
Cough	R05
Cystic fibrosis	E84, P75
Idiopathic pulmonary fibrosis	J84
Influenza	J09, J10, J11
Lung cancer	C33, C34
Lung diseases due to external agents	J60, J61, J62, J63, J64, J66, J67, J68, J70
Mesothelioma	C45
Other diseases of the pleura	J90, J91, J92, J93, J94
Other diseases of the respiratory system	J98, J99
Other diseases of URT	J30, J31, J32, J33, J34, J35, J36, J37, J38, J39
Other respiratory diseases principally affecting the interstitium	J80, J82
Perinatal and congenital respiratory conditions	P22, P23, P24, P25, P26, P27, P28, Q32, Q33, Q34
Pneumonia	J12, J13, J14, J15, J16, J17, J18
Pneumonitis due to solids and liquids	J69
Postprocedural respiratory disorders, not else classified	J95
Pulmonary embolism	126
Pulmonary vascular diseases (other than pul embolism)	J81, I27, I28
Respiratory failure	J96
Sarcoidosis	D86
Sleep apnoea	G47.3
Suppurative and necrotic conditions of the lower respiratory tract	J85, J86
Tuberculosis	A15, A16, B90, J65

Abbreviations

AATD: Alpha-1 Antitrypsin Deficiency

AMAU: Acute Medical Assessment Unit

ASIR: Age Specific Incidence Rate per 100,000

population

BCG: Bacille Calmette Guerin vaccine

BDU: Bed Days Used **CF:** Cystic Fibrosis

CI: Confidence Interval

CIDR: Computerised Infectious Disease Reporting

CIR: Crude Incidence Rate

COPD: Chronic Obstructive Pulmonary Disease

CSO: Central Statistics Office **CTD:** Connective Tissue Disease

D3P3Polio3T3: Diphtheria (3 doses), Pertussis (3 doses), Polio (3 doses), Tetanus (3 doses) vaccines

DALY: Disability-Adjusted Life-Year

DPS: Payment Scheme

DRG: Diagnostic Related Group (AR)

DVT: Deep Venous Thrombosis (DVT)

EARSS: European Antimicrobial Surveillance System

ED: Emergency Department

ERS: European Respiratory Society

EU: European Union

GMS: General Medical Services

Hib3: Haemophilus influenza type b (3 doses) vaccine

HIPE: Hospital Inpatient Enquiry **HPO:** Health Purchasing Office

HPSC: Health Protection Surveillance Centre **ICD:** International Classifications of Disease

ICS: Inhaled Corticosteroids
ILD: Interstitial Lung Disease

IPD: Invasive Pneumococcal Disease

ITS: Irish Thoracic Society

LABA: Long Acting B2 agonist

LAMA: Long Acting Muscarinic antagonist

LOS: Length of Stay

LTOT: Long Term Oxygen Treatment

MersCoV: Middle East Respiratory Syndrome due to

Corona Virus

MMR1: Measles, Mumps and Rubella vaccine

(1 dose)

MOH: Medical Officer of Health

NHQRS: National Healthcare Quality

Reporting System

NIV: Non Invasive Ventilation

NOCA: National Office for Clinical Audit

OECD: Organisation for Economic Co-operation and

Development

OOHs: Out Of Hours

OPD: Out Patients Department

PCRS: Primary Care Re-imbursement Scheme

PE: Pulmonary Embolus

PHIS: Public Health Information System

QALY: Quality Adjusted Life Year **RSV:** Respiratory Syncytial Virus **SABA:** Short Acting B2 agonist

SAMA: Short Acting Muscarinic antagonist **SARS:** Severe Acute Respiratory Syndrome

SMR: Standardised Mortality Rate

TB: Tuberculosis

WHO: World Health Organisation **YLD:** Years Lived with Disability

YPLL: Years of Potential Life Lost

Glossary

Aetiology: The underlying origin or cause(s) of a disease or disorder.

Age-standardised rate: The age-standardised rate for a particular disease or condition is calculated by applying the country's age-specific rates to a standard population. Age standardisation adjusts disease rates to the level they would be if the age distribution of the population was the same either across time, across ethnic or other groups or countries. Age standardisation ensures that comparisons are comparing like with like: using non-standardised rates can make it look like disease rates are different, when in fact the difference lies in what proportion of the population are in the age-group who have the highest or lowest rates of the disease. This enables comparisons to be made between countries with different age-structures and time-periods.

Alveoli: Tiny sacs in the lungs at the furthest end of the airways, where exchange of oxygen and carbon dioxide between air and blood takes place.

Apnoea: Absence of breathing. In the context of sleep apnoea brief periods of apnoea occur during sleep, caused either by an anatomical obstruction in the upper airway or by a failure of respiratory drive.

Cohort study: A longitudinal study in which a population group sharing a common characteristic is followed over time to measure a particular outcome.

Co-morbidity: Conditions that exist alongside another condition, either independently or connectedly.

DALY (disability-adjusted life-year): DALYs represent "the sum of the Years of Life Lost due to premature mortality in the population and the Years Lost due to Disability for incident cases of the health condition" (WHO). DALYs are used to calculate the total disease burden on society.

Dyspnoea: The subjective sensation of difficulty in breathing.

Eosinophils, eosinophilia: A type of white blood cell involved in allergy and some cases of asthma; eosinophilia is the presence of an abnormally large number of eosinophils in the blood or body tissues (e.g. in the lungs).

Herd immunity: The effect whereby vaccination of a significant proportion of individuals in a population has a protective effect on even non-vaccinated individuals because they are less likely to come into contact with an infected person.

Idiopathic: A disease that occurs without a known

Incidence: The incidence of a disease measures the number or rate of new cases of disease occurring in the population, over a specified period such as 12 months. Annual incidence is calculated as the number of new

cases of a disease occurring in 12 months divided by the population who were disease-free at the beginning of the period.

Longitudinal study: A study that tracks the progress of individuals over time.

Median: value or quantity lying at the midpoint of a frequency distribution of observed values or quantities, such that there is an equal probability of falling above or below it.

Obstructive disease: A lung disease in which air flow is limited due to damage to the airways or excessive secretions; asthma and chronic obstructive pulmonary disease (COPD) are obstructive lung diseases.

Oedema: An abnormal accumulation of fluid in tissue.

Particulate matter: A mixture of solid and liquid particles present as pollution in the atmosphere, resulting from processes such as combustion or friction; they are sub-classified by size in μ m, e.g. PM10, PM2.5.

Pertussis: Also known as whooping cough; an infectious disease caused by the bacterium Bordetella pertussis. Vaccination against the disease is available.

Phenotypes: Observable characteristics (physical, biochemical, etc.) produced by the interaction of genetics and environment.

Prevalence: The prevalence of a disease measures the number of cases of existing disease in the population at a given time, or over a period such as the past 12 months. It is calculated as the number of people with the disease divided by the total population, and is usually expressed as a percentage.

Proteases: Enzymes that catalyse the breakdown of proteins by hydrolysing the bonds between amino acids.

QALY (quality-adjusted life-year): A similar concept to DALY, but expressed in terms of quality of life gained, rather than lost to disease or disability.

Restrictive disease: A respiratory disease in which the lungs cannot be expanded normally, due either to disease of the lungs themselves (e.g. interstitial lung diseases) or of the chest wall (e.g. chest deformity or neuromuscular diseases).

Surfactant: A mixture of protein and lipid that reduces the surface tension of fluids in the lung and thereby prevents the collapse of the airways.

Thrombosis: Clotting of blood within a blood vessel, potentially causing tissue death.

World Health Organisation (WHO) European Region: extends from the Atlantic coast to Central Asia. There are two main sources of Europe-wide data on hospital admissions: the WHO-Europe Hospital Morbidity Database (HMDB) and data from the European commission statistical agency, Eurostat.

Acknowledgements

This Respiratory Health of the Nation epidemiological report was written by

Dr Máire O'Connor

Specialist Public Health Medicine/Epidemiologist, Health Service Executive (East)

Ms Eimir Hurley

SPHeRE PhD Scholar/Pharmacist & Biostatistician, Centre for Health Policy and Management, Trinity College Dublin

Ms Suzanne McCormack

Chief Executive Officer, Irish Thoracic Society

Professor Terry O'Connor

Consultant Respiratory Physician, Mercy University Hospital Cork

Encouragement and support were provided by:

Ms Orla Bruton	Department of Public Health, HSE East HSE
Mr Alan Cahill	Department of Health
Dr Tomas Carroll	Alpha-1 Foundation
Dr Suzanne Cotter	Health Protection Surveillance Centre HSE
Dr Phil Downes	Department of Public Health, HSE East HSE
Mr Godfrey Fletcher	Cystic Fibrosis Registry of Ireland
Mr Ian Jarrold	British Lung Foundation
Mr Vincent Kennedy	Department of Health
Prof Pat Manning	National Clinical Programme Asthma
Prof Tim McDonnell	National Clinical Programme COPD
Prof Edward McKone	Cystic Fibrosis Registry of Ireland
Prof Paul McNally	Royal College of Surgeons (Ireland)
Dr Deirdre Mulholland	Department of Public Health, HSE East HSE
Dr Deirdre Murray	National Cancer Control Programme
Prof Charles Normand	Centre for Health Policy and Management, Trinity College Dublin
Dr Joan O'Donnell	Health Protection Surveillance Centre HSE
Mr Ronan O'Kelly	Department of Health
Dr Mary O'Meara	Department of Public Health, HSE East HSE
Ms Aisling Reidy	Department of Health
Ms Bennery Rickard	Regional Librarian, HSE East HSE
Dr David Strachan	St George's, University of London & British Thoracic Society
Prof Steve Thomas	Centre for Health Policy and Management, Trinity College Dublin
Tior Steve momas	centre for recarding and management, finity conege Dublin



